Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/158112
Author(s): Yoo, SGK
Chung, GS
Bahendeka, SK
Sibai, AM
Damasceno, A
Farzadfar, F
Rohloff, P
Houehanou, C
Norov, B
Karki, KB
Azangou-Khyavy, M
Marcus, ME
Aryal, KK
Brant, LCC
Theilmann, M
Cífková, R
Lunet, N
Gurung, MS
Mwangi, JK
Martins, J
Haghshenas, R
Sturua, L
Vollmer, S
Bärnighausen, T
Atun, R
Sussman, JB
Singh, K
Saeedi Moghaddam, S
Guwatudde, D
Geldsetzer, P
Manne-Goehler, J
Huffman, MD
Davies, JI
Flood, D
Title: Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries
Publisher: American Medical Association
Issue Date: 2023
Abstract: "Importance Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. Objective To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. Design, Setting, and Participants Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. Exposures Countries’ per capita income levels and world region; individuals’ socioeconomic demographics. Main Outcomes and Measures Self-reported use of aspirin for secondary prevention of CVD. Results The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.2% [95% CI, 7.7%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. Conclusion and Relevance Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy."
DOI: 10.1001/jama.2023.12905
URI: https://hdl.handle.net/10216/158112
Source: JAMA. 2023 Aug 22;330(8):715-724. doi: 10.1001/jama.2023.12905.
Document Type: Artigo em Revista Científica Internacional
Rights: restrictedAccess
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
yoo-jama23-arcir.pdf
  Restricted Access
695.59 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.